Combination of Anastrozole with Fulvestrant in the Intratumoral Aromatase Xenograft Model
Authors:
- 1 May 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (9) , 3516-3522
Abstract
Although the aromatase inhibitor anastrozole has been shown to be very effective in the treatment of hormone-dependent postmenopausal breast cancer, some patients with advanced disease will develop resistance to treatment. To investigate therapeutic strategies to overcome resistance to anastrozole treatment, we have used an intratumoral aromatase model that simulates postmenopausal breast cancer patients with estrogen-dependent tumors. Growth of the tumors in the mice was inhibited by both anastrozole and fulvestrant compared with the control tumors. Nevertheless, tumors had doubled in size at 5 weeks of treatment. We therefore investigated whether switching the original treatments to anastrozole or fulvestrant alone or the combination of anastrozole plus fulvestrant would reduce tumor growth. The results showed that the best strategy to reverse the insensitivity to anastrozole or fulvestrant is to combine the two agents. Additionally, the tumors treated with anastrozole plus fulvestrant from the beginning had only just doubled their size after 14 weeks of treatment, whereas the anastrozole and fulvestrant treatments alone resulted in 9- and 12-fold increases in tumor size, respectively, in the same time period. Anastrozole plus fulvestrant from the beginning or in sequence was associated with down-regulation of signaling proteins involved in the development of hormonal resistance such as insulin-like growth factor type I receptor β, mitogen-activated protein kinase (MAPK), p-MAPK, AKT, mammalian target of rapamycin (mTOR), p-mTOR, and estrogen receptor α compared with tumors treated with anastrozole or fulvestrant alone. These results suggest that blocking the estrogen receptor and aromatase may delay or reverse the development of resistance to aromatase inhibitors in advanced breast cancer patients. [Cancer Res 2008;68(9):3516–22]Keywords
This publication has 40 references indexed in Scilit:
- Combination of Anastrozole with Fulvestrant in the Intratumoral Aromatase Xenograft ModelCancer Research, 2008
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- What do we know about the mechanisms of aromatase inhibitor resistance?The Journal of Steroid Biochemistry and Molecular Biology, 2006
- Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?British Journal of Cancer, 2006
- Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivityEndocrine-Related Cancer, 2005
- The Role of Growth Factor Receptor Pathways in Human Breast Cancer Cells Adapted to Long-term Estrogen DeprivationCancer Research, 2005
- Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen DeprivationJournal of Biological Chemistry, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Adrenal glands of mouse and rat do not synthesize androgensLife Sciences, 1992
- The significance of steroid metabolism in human cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1990